BDX
$195.03-0.69%
as of close, Oct 27, 2026
☾ AH $195.03 -0.69%
BDX — Becton Dickinson and Company price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDED
130.0140.0150.0160.0170.0180.0190.0200.0210.0220.0020.0M40.0M$195.03—20162019202120242026
2026-10-27
Price$195.03
MA20$169.51
MA50$161.25
Vol5.5M
Key stats#
Price data
- Price
- $195.03
- YTD price return
- +27.83%
- YTD total return
- +30.32%
- Next earnings
- Nov 5, 2026 · Before open
- Market cap
- 53.1B
- Enterprise value
- 70.1B
- Shares outstanding
- 272.4M
- 52W low
- $127.59
- 52W high
- $200.47
- From 52W high
- -2.71%
- From 52W low
- +52.86%
- 52W range
- 93%
- Beta
- 0.20
Volume
- Rel volume
- 0.69×
- 30D volume
- 1.7M
- 30D $ vol
- 309.5M
Insider trading
- Insider net 1W
- −$15K
- Insider net 1M
- −$15K
- Insider net 3M
- −$1.3M
- Insider net 1Y
- −$2.6M
Form 4 transactions by trade date, as filed; latest on file 2026-10-26.
Fundamentals
- Sales (ttm)
- 23.3B
- Sales/share
- $85.36
- EPS (ttm)
- $3.33
- FCF (ttm)
- 3.2B
- FCF/share
- $11.76
- Book value/share
- $89.64
- Net margin
- 4.05%
- ROE
- 3.85%
- ROA
- 1.85%
- Debt / equity
- 0.55×
- Current ratio
- 0.87
Growth (CAGR, ttm) · 10Y
- Sales
- +17.37%+6.87%+3.46%+6.57%
- Net income
- -40.65%-17.30%-13.61%-1.88%
- FCF
- +54.26%+22.48%-5.56%+5.26%
- Shares
- -4.97%-2.08%-1.05%+2.49%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -39.22%-16.90%-12.16%-4.46%
- Sales/share
- +23.51%+9.14%+4.56%+3.97%
- FCF/share
- +62.33%+25.08%-4.55%+2.70%
- Book value/share
- +0.87%+0.09%+1.30%+9.04%
- Dividend/share
- +9.48%+6.13%+5.65%+5.79%
- Price
- +32.66%-0.47%+0.75%+4.26%
- Total return
- +36.18%+1.99%+2.97%+6.32%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 58.5×
- P/OI (ttm)
- 21.4×
- Fwd P/E
- 15.0×
- P/S (ttm)
- 2.3×
- P/B (mrq)
- 2.2×
- P/FCF (ttm)
- 16.6×
- EV/EBITDA (fy)
- 14.1×
- EV/Sales (ttm)
- 3.0×
- FCF yield (ttm)
- 6.03%
- Dividend yield (fwd)
- 2.15%
- Dividend yield (ttm)
- 2.15%
- Dividend/share (fwd)
- $4.20
- Buyback yield (realized, 1y)
- 4.97%
- Shareholder yield (realized, 1y)
- 8.05%
- Buyback yield (cash, ttm)
- 4.71%
- Shareholder yield (cash, ttm)
- 6.96%
Vs own 10Y history
- P/E
- 83rd
- P/OI
- 24th
- P/S
- 17th
- P/B
- 40th
- P/FCF
- 28th
Bar = where today’s multiple sits in BDX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-27#
1D
-0.69%
5D
+0.63%
1M
+6.10%
3M
+22.72%
YTD
+27.83%
1Y
+32.63%
5Y
+3.79%
Recent filings#
- Aug 11Insider sale · Goette Roland (EVP and President, EMEA) sold 2,438 shares for $441K at $180.84
- Aug 6Earnings · Earnings release — EPS $3.23 vs $3.14 est. (+2.9%); revenue $4.98B (+5% y/y) 3.8%
- Jul 228-K · Mike Garrison to Retire from BD
Financial statements
Open full BDX financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +8.32% | +0.22% |
| JNJ | Johnson & Johnson | -0.92% | +0.91% |
| ABBV | AbbVie Inc. | +8.34% | -0.12% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +8.98% | -0.08% |
| MRK | Merck & Co. Inc. | -4.68% | +0.86% |
| NVS | Novartis AG | +7.84% | +1.98% |
| TMO | Thermo Fisher Scientific Inc. | +2.67% | +1.19% |
| AMGN | Amgen Inc. | +8.04% | +0.75% |
